Flavia Borellini is on the board of Cantargia AB, Revolution Medicines, Inc., Kartos Therapeutics, Inc. and Viracta Therapeutics, Inc. and Member of Roche Group.
In the past Dr. Borellini was VP-Global Product & Portfolio Strategy at AstraZeneca PLC and Chief Executive Officer for Acerta Pharma BV (a subsidiary of AstraZeneca PLC) and Vice President-Program Leadership at Onyx Pharmaceuticals, Inc.
Dr. Borellini received a doctorate from Universit? degli Studi di Modena e Reggio Emilia.
|06/08/2023||5,200||Award at $0 per share.||0|
|06/16/2022||5,200||Award at $0 per share.||0|
|06/22/2021||7,234||Award at $0 per share.||0|